Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ProQR Therapeutics N.V. files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.34
3.59
6.51
18.9
15.9
Research and development
31.9
31.2
29.5
46.5
38.1
42.2
50.9
25.1
36.4
44.7
Operating income
-39.6
-40.5
-36.3
-57.4
-42.4
-57.2
-65.2
-31.9
-30.5
-43.4
Interest expense
1.08
4.03
3.41
5.13
1.46
1.08
1.29
Interest income
1.49
0.31
1.52
4.86
2.59
3.25
2.33
Pre-tax income
-39.1
-43.7
-37.1
-56.6
-46.5
-60.7
-64.1
-27.8
-28
-42.2
Income tax
0
0
0.13
0.12
0.12
0.1
-0.08
-0.2
0.02
Net income to minority interests
-0.04
-0.19
-0.27
-0.05
-0.06
0.22
0.38
Net income
-39.1
-43.6
-36.9
-56.5
-46.6
-60.7
-64.4
-28.1
-27.8
-42.2
EPS, basic
-1.67
-1.72
-1.08
-1.38
-0.93
-0.95
-0.90
-0.35
-0.32
-0.40
EPS, diluted
-1.67
-1.72
-1.08
-1.38
-0.93
-0.95
-0.90
-0.35
-0.32
-0.40
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
59.2
48.1
106
112
75.8
188
94.8
119
149
92.4
Receivables
3.75
6.8
Total current assets
62
50.6
108
115
80
191
154
121
154
100
Property, plant and equipment
3.44
2.51
4.22
2.44
18.6
17.5
16.2
Intangible assets
0.09
0.04
Total assets
65.5
53.1
110
118
98.7
210
171
138
168
113
Accounts payable
0.33
0.55
0.14
0.45
0.22
0.19
0.39
1.54
0.02
0.3
Short-term debt
1.96
0.34
1.14
4.77
Total current liabilities
6.71
8.49
8.16
11
10.3
27.6
21
34.2
38.9
32.4
Lease liabilities
15.7
14.7
13.8
13.8
11.1
9.55
Total liabilities
12.4
13.8
17.5
23.7
42.2
96.4
105
96.5
79.4
63.4
Total debt
5.7
7.24
9.39
13.1
17.3
44.1
6.77
4.29
4.58
4.87
Paid-in capital
124
149
236
287
289
398
413
413
484
484
Retained earnings
-75.7
-119
-155
-212
-258
-318
-379
-401
-427
-468
Shareholders' equity
53.1
39.4
92.9
94.3
57.1
114
67.1
41.4
88.6
49.4
Minority interests
-0.04
-0.23
-0.5
-0.55
-0.6
-0.38
Total equity
53.1
39.3
92.7
93.8
56.5
114
66.7
41.4
88.6
49.4
Total liabilities and equity
65.5
53.1
110
118
98.7
210
171
138
168
113
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-39.1
-43.7
-37.1
-56.7
-46.6
-60.8
-64.2
-27.7
-27.8
-42.2
Cash from operations
-34.2
-35
-28.5
-44
-47.1
-26
-68.5
21.5
-36.4
-52.8
Capital expenditures
-2.54
-0.12
-0.31
-0.58
-0.92
-0.48
-0.71
-1.37
-1.42
-1.02
Cash from investing
-2.54
-0.12
-0.31
-0.58
-0.92
-0.43
-0.7
4.28
-4.07
-1.02
Debt issued
0.37
0.3
0.26
2.03
0.58
1.14
Stock issued
25.7
84.2
48.6
108
14.1
71.6
Cash from financing
0.36
26.6
86.5
50.2
14.5
137
-30.9
-2.28
70.3
-1.84
Exchange rate effect
0.74
-2.67
-0.17
0.72
-2.63
1.29
7.35
0.6
0.67
-1.35
Free cash flow
-36.8
-35.1
-28.8
-44.6
-48
-26.5
-69.2
20.2
-37.8
-53.8
Interest paid
0.07
1.11
2.25
3.76
0.79
0.77
0.52
Income taxes paid
0
0
0.06
0.19
0.12
0.1
-0.08
-0.2
0.02
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Operating margin
-273.1%
Operating income / revenue.
Pre-tax margin
-265.1%
Pre-tax income / revenue.
Net margin
-265.2%
Net income / revenue.
FCF margin
-338.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-331.9%
Cash from operations / revenue.
Return on equity (ROE)
-61.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-30.1%
Net income / average total assets.
R&D / revenue
281.2%
Research and development expense / revenue.
Capex / revenue
6.4%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-15.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
64.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-44.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-9.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-2.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-32.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
2.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.09x
Current assets / current liabilities.
Quick ratio
3.06x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.85x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.10x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
4.3%
Total debt / total assets.
Liabilities / assets
56.2%
Total liabilities / total assets.
Net debt
-€87.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€0.40
Net income per basic share, as reported (split-adjusted).
What was ProQR Therapeutics N.V.'s revenue in fiscal 2025?
ProQR Therapeutics N.V. reported revenue of €15.9M for fiscal 2025, 15.9% lower than the year before.
Was ProQR Therapeutics N.V. profitable in fiscal 2025?
No. It reported a net loss of €42.2M.
How much free cash flow did ProQR Therapeutics N.V. generate in fiscal 2025?
Cash from operations of €52.8M minus capital expenditures of €1.0M left free cash flow of -€53.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.